Type I interferons in anticancer immunity.
Identifieur interne : 002676 ( Main/Exploration ); précédent : 002675; suivant : 002677Type I interferons in anticancer immunity.
Auteurs : Laurence Zitvogel [France] ; Lorenzo Galluzzi [France] ; Oliver Kepp [France] ; Mark J. Smyth [Australie] ; Guido Kroemer [France]Source :
- Nature reviews. Immunology [ 1474-1741 ] ; 2015.
Descripteurs français
- KwdFr :
- MESH :
- immunologie : Interféron de type I, Tumeurs.
- usage thérapeutique : Interféron de type I.
- Animaux, Humains, Immunothérapie.
English descriptors
- KwdEn :
- MESH :
- chemical , immunology : Interferon Type I.
- immunology : Neoplasms.
- methods : Immunotherapy.
- chemical , therapeutic use : Interferon Type I.
- Animals, Humans.
Abstract
Type I interferons (IFNs) are known for their key role in antiviral immune responses. In this Review, we discuss accumulating evidence indicating that type I IFNs produced by malignant cells or tumour-infiltrating dendritic cells also control the autocrine or paracrine circuits that underlie cancer immunosurveillance. Many conventional chemotherapeutics, targeted anticancer agents, immunological adjuvants and oncolytic viruses are only fully efficient in the presence of intact type I IFN signalling. Moreover, the intratumoural expression levels of type I IFNs or of IFN-stimulated genes correlate with favourable disease outcome in several cohorts of patients with cancer. Finally, new anticancer immunotherapies are being developed that are based on recombinant type I IFNs, type I IFN-encoding vectors and type I IFN-expressing cells.
DOI: 10.1038/nri3845
PubMed: 26027717
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002B61
- to stream PubMed, to step Curation: 002A89
- to stream PubMed, to step Checkpoint: 002A89
- to stream Ncbi, to step Merge: 002643
- to stream Ncbi, to step Curation: 002643
- to stream Ncbi, to step Checkpoint: 002643
- to stream Main, to step Merge: 002676
- to stream Main, to step Curation: 002676
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Type I interferons in anticancer immunity.</title><author><name sortKey="Zitvogel, Laurence" sort="Zitvogel, Laurence" uniqKey="Zitvogel L" first="Laurence" last="Zitvogel">Laurence Zitvogel</name><affiliation wicri:level="1"><nlm:affiliation>1] [2] INSERM, U1015, F-94800 Villejuif, France. [3] Université Paris Sud/Paris XI, Faculté de Médecine, F-94270 Le Kremlin Bicêtre, France. [4] Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, F-94800 Villejuif, France. [5].</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] [2] INSERM, U1015, F-94800 Villejuif, France. [3] Université Paris Sud/Paris XI, Faculté de Médecine, F-94270 Le Kremlin Bicêtre, France. [4] Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, F-94800 Villejuif</wicri:regionArea><wicri:noRegion>94800 Villejuif</wicri:noRegion><wicri:noRegion>94800 Villejuif</wicri:noRegion></affiliation></author><author><name sortKey="Galluzzi, Lorenzo" sort="Galluzzi, Lorenzo" uniqKey="Galluzzi L" first="Lorenzo" last="Galluzzi">Lorenzo Galluzzi</name><affiliation wicri:level="1"><nlm:affiliation>1] [2] Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, F-75006 Paris, France. [3] INSERM, U1138, F-75006 Paris, France. [4] Université Paris Descartes/Paris V, Sorbonne Paris Cité, F-75006 Paris, France. [5] Université Pierre et Marie Curie/Paris VI, F-75006 Paris, France. [6].</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] [2] Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, F-75006 Paris, France. [3] INSERM, U1138, F-75006 Paris, France. [4] Université Paris Descartes/Paris V, Sorbonne Paris Cité, F-75006 Paris, France. [5] Université Pierre et Marie Curie/Paris VI, F-75006 Paris</wicri:regionArea><wicri:noRegion>75006 Paris</wicri:noRegion><wicri:noRegion>75006 Paris</wicri:noRegion></affiliation></author><author><name sortKey="Kepp, Oliver" sort="Kepp, Oliver" uniqKey="Kepp O" first="Oliver" last="Kepp">Oliver Kepp</name><affiliation wicri:level="1"><nlm:affiliation>1] Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, F-75006 Paris, France. [2] INSERM, U1138, F-75006 Paris, France. [3] Université Paris Descartes/Paris V, Sorbonne Paris Cité, F-75006 Paris, France. [4] Université Pierre et Marie Curie/Paris VI, F-75006 Paris, France. [5] Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, F-94800 Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, F-75006 Paris, France. [2] INSERM, U1138, F-75006 Paris, France. [3] Université Paris Descartes/Paris V, Sorbonne Paris Cité, F-75006 Paris, France. [4] Université Pierre et Marie Curie/Paris VI, F-75006 Paris, France. [5] Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, F-94800 Villejuif</wicri:regionArea><wicri:noRegion>94800 Villejuif</wicri:noRegion><wicri:noRegion>94800 Villejuif</wicri:noRegion></affiliation></author><author><name sortKey="Smyth, Mark J" sort="Smyth, Mark J" uniqKey="Smyth M" first="Mark J" last="Smyth">Mark J. Smyth</name><affiliation wicri:level="1"><nlm:affiliation>1] Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston QLD 4006, Australia. [2] School of Medicine, University of Queensland, Herston QLD 4006, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>1] Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston QLD 4006, Australia. [2] School of Medicine, University of Queensland, Herston QLD 4006</wicri:regionArea><wicri:noRegion>Herston QLD 4006</wicri:noRegion></affiliation></author><author><name sortKey="Kroemer, Guido" sort="Kroemer, Guido" uniqKey="Kroemer G" first="Guido" last="Kroemer">Guido Kroemer</name><affiliation wicri:level="1"><nlm:affiliation>1] Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, F-75006 Paris, France. [2] INSERM, U1138, F-75006 Paris, France. [3] Université Paris Descartes/Paris V, Sorbonne Paris Cité, F-75006 Paris, France. [4] Université Pierre et Marie Curie/Paris VI, F-75006 Paris, France. [5] Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, F-94800 Villejuif, France. [6] Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, F-75015 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, F-75006 Paris, France. [2] INSERM, U1138, F-75006 Paris, France. [3] Université Paris Descartes/Paris V, Sorbonne Paris Cité, F-75006 Paris, France. [4] Université Pierre et Marie Curie/Paris VI, F-75006 Paris, France. [5] Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, F-94800 Villejuif, France. [6] Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, F-75015 Paris</wicri:regionArea><wicri:noRegion>75015 Paris</wicri:noRegion><wicri:noRegion>75015 Paris</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26027717</idno><idno type="pmid">26027717</idno><idno type="doi">10.1038/nri3845</idno><idno type="wicri:Area/PubMed/Corpus">002B61</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002B61</idno><idno type="wicri:Area/PubMed/Curation">002A89</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002A89</idno><idno type="wicri:Area/PubMed/Checkpoint">002A89</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002A89</idno><idno type="wicri:Area/Ncbi/Merge">002643</idno><idno type="wicri:Area/Ncbi/Curation">002643</idno><idno type="wicri:Area/Ncbi/Checkpoint">002643</idno><idno type="wicri:Area/Main/Merge">002676</idno><idno type="wicri:Area/Main/Curation">002676</idno><idno type="wicri:Area/Main/Exploration">002676</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Type I interferons in anticancer immunity.</title><author><name sortKey="Zitvogel, Laurence" sort="Zitvogel, Laurence" uniqKey="Zitvogel L" first="Laurence" last="Zitvogel">Laurence Zitvogel</name><affiliation wicri:level="3"><nlm:affiliation>1] [2] INSERM, U1015, F-94800 Villejuif, France. [3] Université Paris Sud/Paris XI, Faculté de Médecine, F-94270 Le Kremlin Bicêtre, France. [4] Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, F-94800 Villejuif, France. [5].</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] [2] INSERM, U1015, F-94800 Villejuif, France. [3] Université Paris Sud/Paris XI, Faculté de Médecine, F-94270 Le Kremlin Bicêtre, France. [4] Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, F-94800 Villejuif</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Villejuif</settlement></placeName></affiliation></author><author><name sortKey="Galluzzi, Lorenzo" sort="Galluzzi, Lorenzo" uniqKey="Galluzzi L" first="Lorenzo" last="Galluzzi">Lorenzo Galluzzi</name><affiliation wicri:level="3"><nlm:affiliation>1] [2] Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, F-75006 Paris, France. [3] INSERM, U1138, F-75006 Paris, France. [4] Université Paris Descartes/Paris V, Sorbonne Paris Cité, F-75006 Paris, France. [5] Université Pierre et Marie Curie/Paris VI, F-75006 Paris, France. [6].</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] [2] Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, F-75006 Paris, France. [3] INSERM, U1138, F-75006 Paris, France. [4] Université Paris Descartes/Paris V, Sorbonne Paris Cité, F-75006 Paris, France. [5] Université Pierre et Marie Curie/Paris VI, F-75006 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Kepp, Oliver" sort="Kepp, Oliver" uniqKey="Kepp O" first="Oliver" last="Kepp">Oliver Kepp</name><affiliation wicri:level="3"><nlm:affiliation>1] Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, F-75006 Paris, France. [2] INSERM, U1138, F-75006 Paris, France. [3] Université Paris Descartes/Paris V, Sorbonne Paris Cité, F-75006 Paris, France. [4] Université Pierre et Marie Curie/Paris VI, F-75006 Paris, France. [5] Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, F-94800 Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, F-75006 Paris, France. [2] INSERM, U1138, F-75006 Paris, France. [3] Université Paris Descartes/Paris V, Sorbonne Paris Cité, F-75006 Paris, France. [4] Université Pierre et Marie Curie/Paris VI, F-75006 Paris, France. [5] Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, F-94800 Villejuif</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Villejuif</settlement></placeName></affiliation></author><author><name sortKey="Smyth, Mark J" sort="Smyth, Mark J" uniqKey="Smyth M" first="Mark J" last="Smyth">Mark J. Smyth</name><affiliation wicri:level="1"><nlm:affiliation>1] Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston QLD 4006, Australia. [2] School of Medicine, University of Queensland, Herston QLD 4006, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>1] Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston QLD 4006, Australia. [2] School of Medicine, University of Queensland, Herston QLD 4006</wicri:regionArea><wicri:noRegion>Herston QLD 4006</wicri:noRegion></affiliation></author><author><name sortKey="Kroemer, Guido" sort="Kroemer, Guido" uniqKey="Kroemer G" first="Guido" last="Kroemer">Guido Kroemer</name><affiliation wicri:level="1"><nlm:affiliation>1] Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, F-75006 Paris, France. [2] INSERM, U1138, F-75006 Paris, France. [3] Université Paris Descartes/Paris V, Sorbonne Paris Cité, F-75006 Paris, France. [4] Université Pierre et Marie Curie/Paris VI, F-75006 Paris, France. [5] Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, F-94800 Villejuif, France. [6] Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, F-75015 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, F-75006 Paris, France. [2] INSERM, U1138, F-75006 Paris, France. [3] Université Paris Descartes/Paris V, Sorbonne Paris Cité, F-75006 Paris, France. [4] Université Pierre et Marie Curie/Paris VI, F-75006 Paris, France. [5] Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, F-94800 Villejuif, France. [6] Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, F-75015 Paris</wicri:regionArea><wicri:noRegion>75015 Paris</wicri:noRegion><wicri:noRegion>75015 Paris</wicri:noRegion></affiliation></author></analytic><series><title level="j">Nature reviews. Immunology</title><idno type="eISSN">1474-1741</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Humans</term><term>Immunotherapy (methods)</term><term>Interferon Type I (immunology)</term><term>Interferon Type I (therapeutic use)</term><term>Neoplasms (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Humains</term><term>Immunothérapie ()</term><term>Interféron de type I (immunologie)</term><term>Interféron de type I (usage thérapeutique)</term><term>Tumeurs (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Interferon Type I</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Interféron de type I</term><term>Tumeurs</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Immunotherapy</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Interferon Type I</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Interféron de type I</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Humains</term><term>Immunothérapie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Type I interferons (IFNs) are known for their key role in antiviral immune responses. In this Review, we discuss accumulating evidence indicating that type I IFNs produced by malignant cells or tumour-infiltrating dendritic cells also control the autocrine or paracrine circuits that underlie cancer immunosurveillance. Many conventional chemotherapeutics, targeted anticancer agents, immunological adjuvants and oncolytic viruses are only fully efficient in the presence of intact type I IFN signalling. Moreover, the intratumoural expression levels of type I IFNs or of IFN-stimulated genes correlate with favourable disease outcome in several cohorts of patients with cancer. Finally, new anticancer immunotherapies are being developed that are based on recombinant type I IFNs, type I IFN-encoding vectors and type I IFN-expressing cells.</div></front></TEI><affiliations><list><country><li>Australie</li><li>France</li></country><region><li>Île-de-France</li></region><settlement><li>Paris</li><li>Villejuif</li></settlement></list><tree><country name="France"><region name="Île-de-France"><name sortKey="Zitvogel, Laurence" sort="Zitvogel, Laurence" uniqKey="Zitvogel L" first="Laurence" last="Zitvogel">Laurence Zitvogel</name></region><name sortKey="Galluzzi, Lorenzo" sort="Galluzzi, Lorenzo" uniqKey="Galluzzi L" first="Lorenzo" last="Galluzzi">Lorenzo Galluzzi</name><name sortKey="Kepp, Oliver" sort="Kepp, Oliver" uniqKey="Kepp O" first="Oliver" last="Kepp">Oliver Kepp</name><name sortKey="Kroemer, Guido" sort="Kroemer, Guido" uniqKey="Kroemer G" first="Guido" last="Kroemer">Guido Kroemer</name></country><country name="Australie"><noRegion><name sortKey="Smyth, Mark J" sort="Smyth, Mark J" uniqKey="Smyth M" first="Mark J" last="Smyth">Mark J. Smyth</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002676 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002676 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26027717
|texte= Type I interferons in anticancer immunity.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26027717" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |